DOCSLIB.ORG

Adderall Cheat Sheet by Brandidavis0 Via Cheatography.Com/61682/Cs/15917

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adderall Cheat Sheet by Brandidavis0 Via Cheatography.Com/61682/Cs/15917 Adderall Cheat Sheet by brandidavis0 via cheatography.com/61682/cs/15917/ Adverse Reactio​ ns Addic​ tion Potenti​ al Age related dosage side effects (cont) Symptoms of Withdra​ wal Negat​ ive: Posit​ ive Adderall will directly affect the nausea Intense craving for more mesolimbic reward pathway in Adderall. You might be unable Increase in Increase anxiety an individ​ ual’s brain. As a result feel normal without it. BP Concent​ ration dry mouth of this function, Adderall has a Sleep problems. Some people Sudden Improved weight loss relatively high potential for alternate between insomnia Stroke Perform​ ance addiction and abuse, headache (trouble falling or staying Heart Attack ​ particularly if the drug is abused agitation asleep) and sleeping too much. Death or taken by individ​ uals who are dizziness Intense hunger not classified with the Diminish Appetite Anxiety and irritab​ ility aforeme​ nti​ oned conditi​ ons. fast heart rate diarrhea Panic attacks Infor​ mat​ ion Age related dosage side weakness Fatigue or lack of energy Generic Brand Class​ ifi​ ca​ effects urinary tract infections Unhappi​ ness Name: Name: tion: In children 6 to 12 loss of Depression d- Adderall Psychos​ ti​ years old, side appetite Note Phobias or panic attacks amphe​ ta mulant effects may include: mine For those individ​ uals who take and Suicidal thoughts insomnia l-amphe​ tamine experience adverse side effects with Ritalin, stomach Adderall is often recomme​ nded as an How does it works pain effective substit​ ute. Clinical Use Extended Release: nausea Used to treat and Pictu​ res: The pill achieves ADHD; Narcolepsy vomiting maximum plasma fever concent​ ration in roughly Composed Of: seven hours. When nervous​ n Ampheta​ mine Salts: Racemic ess ingested, the extended Ampheta​ mine Aspartate formula​ tion of Adderall uses In teens, the most loss of Monohyd​ rate, Racemic the Microtol common side appetite Ampheta​ mine Sulfate, extende​ d-r​ elease delivery effects include: Dextroa​ mph​ eta​ mine system, which incorpo​ rates Saccaride and insomnia two types of beads into the Dextroa​ mph​ eta​ mine Sulfate stomach subject’s system. The first hoard of beads dissolves Purpo​ se pain immedia​ tely, releasing half nervous​ n Stimulates the brain and of the medicat​ ion, while the ess increases the attention span second set dissolves at a ​ as well as the concentration weight slower rate, releasing the by increasing the amount of loss medication four hours later. dopamine and Side effects in loss of norepin​ eph​ rine in the brain. Instant Release: adults may include: appetite Adderall acts as a potent Reaches maximum insomnia dopamine reuptake inhibitor plasma concent​ ration and norepin​ ephine reuptake within three hours. inhibitor. By brandidavis0 Not published yet. Sponsored by Readability-Score.com cheatography.com/brandidavis0/ Last updated 27th May, 2018. Measure your website readability! Page 1 of 2. https://readability-score.com Adderall Cheat Sheet by brandidavis0 via cheatography.com/61682/cs/15917/ High Dosage; Chronic Intoxic​ ati​ on Feelings of euphoria and excitement Severe dermatosis (a skin condition) Insomnia Hyperac​ tivity Irritab​ ility Changes in persona​ lity Do not take if certain medical conditi​ ons heart disease high blood pressure hardening of the arteries hyperth​ yro​ idism glaucoma Similar to other powerful stimulant drugs Meth Cocaine By brandidavis0 Not published yet. Sponsored by Readability-Score.com cheatography.com/brandidavis0/ Last updated 27th May, 2018. Measure your website readability! Page 2 of 2. https://readability-score.com.
Load more

Recommended publications
  • Methamphetamine (Canadian Drug Summary)
    www.ccsa.ca • www.ccdus.ca March 2020 Canadian Drug Summary Methamphetamine Key Points • The prevalence of methamphetamine use in the Canadian population is low (~0.2%). • Several jurisdictions report at least a three-fold increase in the use of methamphetamine over the past five years among individuals accessing treatment or harm reduction services. • Notable increases for rates of criminal violations involving methamphetamine have been observed in the last five years (2013–2018). Introduction Methamphetamine is a synthetic drug classified as a central nervous system (CNS) stimulant or psychostimulant. CNS stimulants cover a wide range of substances that act on the body by increasing the level of activity of the CNS and include caffeine, nicotine, amphetamine (e.g., Adderall®), methylphenidate (e.g., Ritalin®), MDMA (“ecstasy”), cocaine (including crack cocaine) and methamphetamine (including crystal meth).1,2 While both methamphetamine and amphetamine are psychostimulants and often grouped together, they are different drugs. A slight chemical modification of amphetamine produces methamphetamine, which has a different pharmacological profile that results in a larger release of certain neurochemicals in the brain and a stronger and more rapid physiological response. Some amphetamines are prescribed in Canada for attention-deficit hyperactivity disorder (ADHD) and narcolepsy (e.g., Adderall and Vyvanse®), but methamphetamine use is currently illegal. Methamphetamine is often made in illegal, clandestine laboratories with commonly available, inexpensive chemicals, such as ephedrine and pseudoephedrine, found in medications, among other sources. The use of these medications as precursor chemicals for methamphetamine led to stricter regulations introduced in Canada in 2006, limiting access to them by requiring they be kept behind the counter of pharmacies.3 Illegal production can be dangerous due to the toxicity of the chemicals used and the high risk of explosions.
    [Show full text]
  • A Comparison of Ritalin and Adderall: Efficacy and Time-Course in Children with Attention-Deficit/Hyperactivity Disorder
    A Comparison of Ritalin and Adderall: Efficacy and Time-course in Children With Attention-deficit/Hyperactivity Disorder William E. Pelham, PhD*; Helen R. Aronoff, MD‡; Jill K. Midlam, MA*; Cheri J. Shapiro, PhD*; Elizabeth M. Gnagy, BS*; Andrea M. Chronis, BS*; Adia N. Onyango, BS*; Gregory Forehand, BS*; Anh Nguyen, BS*; and James Waxmonsky, MD‡ ABSTRACT. Objective. Very little research has fo- ratings were also made for evening behavior to assess cused on the efficacy of Adderall (Shire-Richwood Inc, possible rebound, and side effects ratings were obtained Florence, KY) in the treatment of children with attention- from parents, counselors, and teachers. Parents, counsel- deficit/hyperactivity disorder (ADHD), and no studies ors, and teachers also rated their perceptions of medica- have compared it with standardized doses of Ritalin tion status and whether they recommended the contin- (Novartis Pharmaceuticals, East Hanover, NJ). It is ued use of the medication given that day. Finally, a thought that Adderall has a longer half-life than Ritalin clinical team made recommendations for treatment tak- and might minimize the loss of efficacy that occurs 4 or 5 ing into account each child’s individual response. hours after Ritalin ingestion. We compared two doses of Results. Both drugs were routinely superior to pla- Ritalin and Adderall in the treatment of ADHD in chil- cebo and produced dramatic improvements in rates of dren in an acute study and assessed the medications’ negative behavior, academic productivity, and staff/par- time courses. ent ratings of behavior. The doses of Adderall that were Design. Within-subject, double-blind, placebo-con- assessed produced greater improvement than did the as- trolled, crossover design lasting 6 weeks.
    [Show full text]
  • (Adhd) Quantity Limitation Utilization Management Criteria
    ATTENTION- DEFICIT HYPERACTIVITY DISORDER (ADHD) QUANTITY LIMITATION UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: Stimulants and Non-Stimulants BRAND (generic) NAMES: Adderall® (amphetamine/dextroamphetamine) Adderall XR® (amphetamine/ dextroamphetamine ER) Adzenys XR-ODTTM (amphetamine ER dispersible) Aptensio XR® (methylphenidate ER) Concerta® (methylphenidate ER) Daytrana® (methylphenidate transdermal patch) Dextroampthetamine (DextroStat®) Dexedrine® (dextroamphetamine ER) DyanavelTM XR (amphetamine ER) Focalin XR® (dexmethylphenidate ER) Focalin® (dexmethylphenidate) Intuniv® (guanfacine ER) Kapvay® (clonidine ER) Metadate CD® (methylphenidate ER) Metadate ER® (methylphenidate ER) Methylin® (methylphenidate) Procentra® (dextroamphetamine) QuillichewTM (methylphenidate ER) Quillivant XR® (methylphenidate ER) Ritalin® (methylphenidate) Ritalin® LA (methylphenidate ER) Ritalin® SR (methylphenidate ER) Strattera® (atomoxetine) Vyvanse® (lisdexamphetamine) Zenzedi® (dextroamphetamine) COVERAGE AUTHORIZATION CRITERIA Non-formulary medications - Medications included in this criterion that are not part of ASO Net Results or Essential Formularies are subject to a trial and failure of up to TWO formulary alternatives that are clinically appropriate, to treat the same condition, prior to approval (see Non-formulary Exception Criteria for detailed limitations). Quantities above the program set limit (see pgs 2-4) for ADHD agents will be approved when the following is met: 1. The quantity (dose) requested is for documented titration purposes at the initiation of therapy (authorization for a 90 day titration period); AND 2. The prescribed dose cannot be achieved using a lesser quantity of a higher strength; AND 3. The quantity (dose) requested does not exceed the maximum FDA labeled dose, when specified, or to the safest studied dose per the manufacturer’s product insert; OR BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans.
    [Show full text]
  • Stimulant and Related Medications: US Food and Drug
    Stimulant and Related Medications: U.S. Food and Drug Administration-Approved Indications and Dosages for Use in Adults The therapeutic dosing recommendations for stimulant and related medications are based on U.S. Food and Drug Administration (FDA)-approved product labeling. Nevertheless, the dosing regimen is adjusted according to a patient’s individual response to pharmacotherapy. The FDA-approved dosages and indications for the use of stimulant and related medications in adults are provided in this table. All medication doses listed are for oral administration. Information on the generic availability of the stimulant and related medications can be found by searching the Electronic Orange Book at https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm on the FDA website. Generic Medication Indication Dosing Information Other Information Availability amphetamine/dextroamphetamine ADHD Initial dose: May increase daily dose by 5 mg at Yes mixed salts[1] 5 mg once or twice a day; weekly intervals until optimal response Maximum dose: 40 mg per day is achieved. Only in rare cases will it be necessary to exceed a total of 40 mg per day. amphetamine/dextroamphetamine narcolepsy Initial dose: 10 mg per day; May increase daily dose by 10 mg at Yes mixed salts Usual dose: weekly intervals until optimal response 5 mg to 60 mg per day is achieved. Take first dose in divided doses upon awakening. amphetamine/dextroamphetamine ADHD Recommended dose: Patients switching from regular-release Yes mixed salts ER*[2] 20 mg once a day amphetamine/dextroamphetamine mixed salts may take the same total daily dose once a day. armodafinil[3] narcolepsy Recommended dose: Take as a single dose in the morning.
    [Show full text]
  • What Every Clinician Should Know Before Starting a Patient on Meds
    CARING FOR CHILDREN WITH ADHD: A RESOURCE TOOLKIT FOR CLINICIANS, 2ND EDITION Basic Facts: What Every Clinician Should Know Before Starting a Patient on Medication Studies have shown that treatment for attention-deficit/ • If you reach the maximum recommended dose without • hyperactivity disorder (ADHD) with medication is effective in noticeable improvement in symptoms, try a different stimulant treating the symptoms of ADHD alone or in combination with medication class. Approximately 80% of children will respond to behavioral interventions. at least 1 of the 2 stimulant classes tried. • Stimulant medications also improve academic productivity but • When changing medications, be careful about the dose not cognitive abilities or academic skills. equivalence of different stimulant medication classes; in general, equivalent doses for dexmethylphenidate and Stimulants can help reduce oppositional, aggressive, impulsive, • amphetamine-based stimulants are approximately half of a and delinquent behaviors in some children. methylphenidate dose. Several types of medications are Food and Drug Administration Non-stimulant medications may require 2 or more weeks to see • (FDA)-approved for the treatment of ADHD. • effects, so you should titrate up more slowly than you would • Stimulant medications: methylphenidate, dexmethylphenidate, for stimulant medications. Obtaining follow-up rating scales is dextroamphetamine, mixed amphetamine salts, even more important than for stimulant medications because lisdexamfetamine changes are more gradual. • Non-stimulant medications: atomoxetine, and extended-release • Managing side effects effectively can improve adherence to and guanfacine and clonidine satisfaction with stimulant medications. When choosing which stimulant and dose to start first, consider • Common side effects to discuss with families include • stomachache, headache, decreased appetite, sleep problems, Family preference and experience with the medication, including • and behavioral rebound.
    [Show full text]
  • Alcohol Mixed with Other Drugs
    Alcohol Mixed with Other Drugs Stimulants Stimulants or “uppers”: Drugs that temporarily +increase alertness and energy Examples: Adderall, Ritalin, cocaine, methamphetamine FOCUS: Alcohol + Adderall Adderall: Used to treat ADHD and narcolepsy. Some students misuse Adderall in hopes it will help them study. “Misuse” is defined as taking a medication that was not prescribed to you, taking more Alcohol than what was prescribed to you or taking it for a dierent purpose than prescribed. Eects: Because alcohol is a depressant Use CUPS to remember the and Adderall is a stimulant, Adderall will symptoms of alcohol poisoning: mask alcohol’s eects. Mixing alcohol with • Cold, clammy, pale or bluish skin. a stimulant makes you less aware of alcohol's • Unconscious or unable to be roused. intoxicating eects, which can result in an • Puking repeatedly or uncontrollably. overdose or death. Additionally, mixing alcohol with Adderall (or any other stimulant) • Slow or irregular breathing. can cause an irregular heartbeat and cause cardiovascular complications. Stat: 4.3 percent of UC Davis undergraduates reported using a prescription stimulant in the last 12 months that was not prescribed to them. Sedative Depressants or “downers”: Sedating drugs +that reduce stimulation Examples: opiates, Xanax, Valium FOCUS: Alcohol + Opiates/Opioids Opiates: A group of drugs that are used for treating pain -examples: heroin, morphine, codeine, oxycontin, vicodin, fentanyl Alcohol Eects: When alcohol and opioids are Symptoms: taken at the same time, the sedative • Slow or irregular breathing eects of both drugs will magnify. This • Lowered pulse and can depress or even stop involuntary blood pressure functions, such as breathing, and will • Unconscious or unable increase the risk of overdose and death.
    [Show full text]
  • Phenylmorpholines and Analogues Thereof Phenylmorpholine Und Analoge Davon Phenylmorpholines Et Analogues De Celles-Ci
    (19) TZZ __T (11) EP 2 571 858 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 265/30 (2006.01) A61K 31/5375 (2006.01) 20.06.2018 Bulletin 2018/25 A61P 25/24 (2006.01) A61P 25/16 (2006.01) A61P 25/18 (2006.01) (21) Application number: 11723158.9 (86) International application number: (22) Date of filing: 20.05.2011 PCT/US2011/037361 (87) International publication number: WO 2011/146850 (24.11.2011 Gazette 2011/47) (54) PHENYLMORPHOLINES AND ANALOGUES THEREOF PHENYLMORPHOLINE UND ANALOGE DAVON PHENYLMORPHOLINES ET ANALOGUES DE CELLES-CI (84) Designated Contracting States: • DECKER, Ann Marie AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Durham, North Carolina 27713 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hoeger, Stellrecht & Partner Patentanwälte mbB (30) Priority: 21.05.2010 US 347259 P Uhlandstrasse 14c 70182 Stuttgart (DE) (43) Date of publication of application: 27.03.2013 Bulletin 2013/13 (56) References cited: WO-A1-2004/052372 WO-A1-2008/026046 (73) Proprietors: WO-A1-2008/087512 DE-B- 1 135 464 • Research Triangle Institute FR-A- 1 397 563 GB-A- 883 220 Research Triangle Park, North Carolina 27709 GB-A- 899 386 US-A1- 2005 267 096 (US) • United States of America, as represented by • R.A. GLENNON ET AL.: "Beta-Oxygenated The Secretary, Department of Health and Human Analogues of the 5-HT2A Serotonin Receptor Services Agonist Bethesda, Maryland 20892-7660 (US) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopro pane", JOURNAL OF MEDICINAL CHEMISTRY, (72) Inventors: vol.
    [Show full text]
  • Chronic Amphetamine Exposure Causes Long Term Effects on Dopamine Uptake in Cultured Cells Nafisa Ferdous
    University of North Dakota UND Scholarly Commons Theses and Dissertations Theses, Dissertations, and Senior Projects January 2016 Chronic Amphetamine Exposure Causes Long Term Effects On Dopamine Uptake In Cultured Cells Nafisa Ferdous Follow this and additional works at: https://commons.und.edu/theses Recommended Citation Ferdous, Nafisa, "Chronic Amphetamine Exposure Causes Long Term Effects On Dopamine Uptake In Cultured Cells" (2016). Theses and Dissertations. 2016. https://commons.und.edu/theses/2016 This Thesis is brought to you for free and open access by the Theses, Dissertations, and Senior Projects at UND Scholarly Commons. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of UND Scholarly Commons. For more information, please contact [email protected]. CHRONIC AMPHETAMINE EXPOSURE CAUSES LONG TERM EFFECTS ON DOPAMINE UPTAKE IN CULTURED CELLS By Nafisa Ferdous Bachelor of Science, North South University, Bangladesh 2012 A Thesis submitted to the Graduate Faculty of the University of North Dakota in partial fulfillment of the requirements for the degree of Master of Science Grand Forks, North Dakota December 2016 ii PERMISSION Title Chronic amphetamine exposure causes long term effects on dopamine uptake in cultured cells Department Biomedical Sciences Degree Master of Science In presenting this thesis in partial fulfillment of the requirements for a graduate degree from the University of North Dakota, I agree that the library of this University shall make it freely available for inspection. I further agree that permission for extensive copying for scholarly purposes may be granted by the professor who supervised my thesis work or, in his absence, by the Chairperson of the department or the Dean of the School of Graduate Studies.
    [Show full text]
  • Adult ADHD Treatment
    Adult ADHD Treatment Main Points and Tips: • A cure for ADHD does not currently exist. Treatment is shown to be effective in reducing signs of ADHD and improving qual- ity of life but it does not all symptoms can be ameliorated with treatment. Treatment Goal: • Primary goal of treatment is to minimize the impact of ADHD symptoms on patient function while maximizing the patient’s ability to compensate or cope with any remaining difficulties. General Approach: • Treatment includes psychosocial interventions and pharmacotherapy. • Psychosocial interventions are designed to help patients learn to manage and cope with their symptoms and function better in life. • Pharmacological treatments have risks and benefits, and may sometimes be limited due to safety concerns. • If the patient has comorbid conditions, treat the more severe disorder(s) first. For example, if the patient is both depressed and has ADHD—if the ADHD is having the biggest impact on the patient’s functioning—treat ADHD first. • Once the most severe disorder is treated, it is important to continue treatment of other comorbid disorders (e.g., depres- sion and ADHD both need to be treated in order to maximize treatment effectiveness). • Education about ADHD is essential to assist the patient in making informed decisions about pharmacotherapy and the im- portance of behavioral and lifestyle changes. • Pharmacotherapy should be considered one component of a comprehensive treatment program that addresses psychologi- cal, behavioral, educational, or occupational needs. • Consider long-acting stimulants for all patients. Avoid short-acting or immediate-release stimulants as they have a higher abuse and diversion potential • Initiate ADHD medications at the lowest possible dose and titrate slowly.
    [Show full text]
  • MEDICATION GUIDE Adderall (ADD-Ur-All) (CII
    MEDICATION GUIDE Adderall® (ADD-ur-all) (CII) (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product)) Read the Medication Guide that comes with Adderall® before you or your child starts taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about you or your child’s treatment with Adderall® . What is the most important information I should know about Adderall® ? The following have been reported with use of Adderall® and other stimulant medicines. 1. Heart-Related Problems: • sudden death in patients who have heart problems or heart defects • stroke and heart attack in adults • increased blood pressure and heart rate Tell your doctor if you or your child have any heart problems, heart defects, high blood pressure, or a family history of these problems. Your doctor should check you or your child carefully for heart problems before starting Adderall® . Your doctor should check your or your child’s blood pressure and heart rate regularly during treatment with Adderall® . Call your doctor right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting while taking Adderall® . 2. Mental (Psychiatric) Problems: All Patients • new or worse behavior and thought problems • new or worse bipolar illness • new or worse aggressive behavior or hostility Children and Teenagers • new psychotic symptoms (such as hearing voices, believing things that are not true, are suspicious) or new manic symptoms Tell your doctor about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression.
    [Show full text]
  • The Cognition-Enhancing Effects of Psychostimulants Involve Direct Action in the Prefrontal Cortex
    Rowan University Rowan Digital Works School of Osteopathic Medicine Faculty Scholarship School of Osteopathic Medicine 6-1-2015 The Cognition-Enhancing Effects of Psychostimulants Involve Direct Action in the Prefrontal Cortex Robert C. Spencer University of Wisconsin-Madison David M. DeVilbiss Rowan University School of Osteopathic Medicine Craig Berridge University of Wisconsin-Madison Follow this and additional works at: https://rdw.rowan.edu/som_facpub Part of the Neuroscience and Neurobiology Commons, Pharmacology Commons, and the Psychiatry Commons Recommended Citation Spencer RC, Devilbiss DM, Berridge CW. The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex. Biol Psychiatry. 2015 Jun 1;77(11):940-50. Epub 2014 Sep 28. doi: 10.1016/j.biopsych.2014.09.013. PMID: 25499957. PMCID: PMC4377121. This Article is brought to you for free and open access by the School of Osteopathic Medicine at Rowan Digital Works. It has been accepted for inclusion in School of Osteopathic Medicine Faculty Scholarship by an authorized administrator of Rowan Digital Works. HHS Public Access Author manuscript Author Manuscript Author ManuscriptBiol Psychiatry Author Manuscript. Author Author Manuscript manuscript; available in PMC 2016 June 01. Published in final edited form as: Biol Psychiatry. 2015 June 1; 77(11): 940–950. doi:10.1016/j.biopsych.2014.09.013. The Cognition-Enhancing Effects of Psychostimulants Involve Direct Action in the Prefrontal Cortex Robert C. Spencer, David M. Devilbiss, and Craig W. Berridge* Department of Psychology, University of Wisconsin, Madison, WI Abstract Psychostimulants are highly effective in the treatment of attention deficit hyperactivity disorder (ADHD). The clinical efficacy of these drugs is strongly linked to their ability to improve cognition dependent on the prefrontal cortex (PFC) and extended frontostriatal circuit.
    [Show full text]
  • 2016-2018 Stimulant Overdose Surveillance Preliminary Report
    Stimulant Overdose Surveillance Preliminary Report Georgia 2016-2018 Drug Surveillance Unit Epidemiology Section Georgia Department of Public Health https://dph.georgia.gov/drug-overdose-surveillance-unit Stimulant Overdose Surveillance Report, Georgia, 2018 / Page 1 Stimulant Overdose Surveillance, Georgia, 2018 The purpose of this report is to describe fatal (mortality) and nonfatal (morbidity) stimulant-involved hospitalizations and deaths in Georgia during 2016, 2017, and 2018, including those involving prescription stimulants (e.g. Adderall, Ritalin, etc.), and illicit stimulants (e.g., cocaine, methamphetamine, etc.). Stimulant overdose data was analyzed by the Georgia Department of Public Health (DPH) Epidemiology Program, Drug Surveillance Unit, using Georgia hospital discharge inpatient and emergency department (ED) visit data, and DPH Vital Records death data. Key Findings Stimulant-involved morbidity and mortality is increasing in Georgia. Mortality • From 2016 to 2018, overdose deaths involving stimulants increased by 44%, from 487 to 703 deaths. • From 2017 to 2018, overdose deaths involving stimulants increased by 11%, from 631 to 703 deaths. • In 2018, amphetamines were involved in more deaths than any other stimulant. • White persons were 1.6 times more likely to die from a drug overdose involving stimulants and 5.5 times more likely to die from a drug overdose involving amphetamines than Black persons, yet Black persons were 1.5 times more likely than white persons to die from a drug overdose involving cocaine. • Males aged 25-64 years died more frequently from stimulant-involved overdose than males in any other age category and females of all age categories. Males aged 35-44 years had the highest stimulant-related death rate.
    [Show full text]